Welcome to our dedicated page for Structure Therapeutics news (Ticker: GPCR), a resource for investors and traders seeking the latest updates and insights on Structure Therapeutics stock.
Structure Therapeutics Inc. develops oral small-molecule therapeutics for chronic metabolic diseases, with a focus on obesity. The clinical-stage global biopharmaceutical company uses a structure-based drug discovery platform and GPCR-targeted pipeline to advance wholly owned compounds, including aleniglipron, an oral nonpeptide GLP-1 receptor agonist, and ACCG-2671, an oral amylin receptor agonist.
Recurring company updates include clinical data from the ACCESS aleniglipron program, obesity and weight-management research presentations, financial results, research-and-development funding, ADS and warrant financings, and leadership or governance changes. The company’s American depositary shares trade under GPCR, with each ADS representing three ordinary shares.
Structure Therapeutics (GPCR) reported positive clinical data for its oral small molecule amylin agonist ACCG-2671 and GLP-1 agonist aleniglipron for chronic weight management. In a Phase 1/2a single ascending dose trial, ACCG-2671 showed a terminal half-life of about 6 days supporting potential once-weekly dosing, no serious adverse events or drug-induced liver injury, and pharmacodynamic activity including a mean 3.3% body weight reduction 24 days after a single 10 mg dose and about 60% reduction in CTX-1, a bone resorption biomarker. The multiple ascending dose portion in participants with obesity is underway with topline data expected in 1H 2027.
In the 72‑week ACCESS open-label extension, once-daily aleniglipron 180 mg produced up to 16.2% mean weight loss with no observed plateau; more than one-third of participants in the 90 mg and 120 mg cohorts lost over 20% of body weight, with mean absolute reductions of 35.9 and 40.5 pounds. Fewer than 5% discontinued due to adverse events, and no drug-induced liver injury or off-target safety signals were seen. Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 trials are enrolling, with topline data expected in 2H 2028.
Structure Therapeutics (GPCR) will participate in three healthcare investor conferences in September 2026, featuring fireside chats and 1x1 meetings.
Events include the Cantor Global Healthcare Conference on Thursday, September 10 (3:55–4:25 PM EDT), the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16 (10:45–11:20 AM EDT), and Bernstein’s 3rd Annual Healthcare Forum on Wednesday, September 23 (3:00–3:40 PM EDT), all in New York, NY. Live and archived webcasts will be available on the company’s investor relations website for at least 90 days.
Structure Therapeutics (NASDAQ: GPCR) reported second quarter 2026 results and key pipeline milestones, led by dosing first patients in the Phase 3 ACCOMPLISH program of oral GLP-1 agonist aleniglipron for chronic weight management. ACCOMPLISH-1 will enroll up to 3,600 adults with obesity or overweight plus comorbidity, and ACCOMPLISH-2 up to 1,100 adults with obesity or overweight and type 2 diabetes, with three maintenance doses (45, 90, 180 mg) versus placebo.
The company remains on track to report multiple aleniglipron data readouts in 2H 2026 and advance dual amylin/calcitonin receptor agonists ACCG-2671 (Phase 1 SAD, MAD start Q3 2026) and ACCG-3535 (Phase 1 start Q4 2026), and to initiate a GLP-1/amylin combination trial in Q4 2026. Structure appointed obesity and diabetes commercial veteran John Berrios as CCO. Cash, cash equivalents and short-term investments totaled $1.3 billion as of June 30, 2026, which the company expects will fund projected operations and key clinical milestones through 2028. Q2 2026 R&D expenses were $100.1 million, G&A expenses $18.6 million, and net loss $106.2 million.
Structure Therapeutics (NASDAQ:GPCR) reported detailed Phase 2b ACCESS results for aleniglipron, a once-daily oral GLP-1 receptor agonist for obesity, published in Nature Medicine and presented at ADA 2026.
Data showed dose-dependent, statistically significant weight loss, up to 16.2% in the open-label extension, a 10.4% discontinuation rate, and GI side effects typical of GLP-1 drugs. A Phase 3 program is planned to start in Q3 2026 using a 2.5 mg starting dose, with multiple additional obesity pipeline presentations at ADA.
Structure Therapeutics (NASDAQ: GPCR) will participate in two June 2026 healthcare investor conferences, featuring fireside chats and 1x1 meetings.
Events include the Jefferies Global Healthcare Conference on June 3 in New York and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 in Miami, with live and archived webcasts available for 90 days.
Structure Therapeutics (NASDAQ: GPCR) reported Q1 2026 results and a clinical update on May 7, 2026. Key highlights: aleniglipron Phase 2 ACCESS II showed placebo-adjusted weight loss up to 16.3% at 44 weeks; the company received positive end-of-Phase 2 FDA feedback and plans Phase 3 initiation in Q3 2026. Cash, cash equivalents and short-term investments totaled $1.5 billion as of March 31, 2026, projected to fund operations through end of 2028.
Structure Therapeutics (NASDAQ: GPCR) will present multiple clinical and preclinical posters and an oral presentation at the American Diabetes Association 86th Scientific Sessions, June 5–8, 2026, in New Orleans.
Presentations include ACCESS Phase 2b data reporting meaningful weight reductions, a Phase 2 ACCESS II safety/tolerability poster (doses up to 240 mg), a lower‑starting‑dose GI tolerability analysis, and combination and comparative amylin/GLP‑1 preclinical posters.
Structure Therapeutics (NASDAQ: GPCR) appointed Matthew Lang, J.D. as Chief Operating Officer and General Counsel effective April 14, 2026. Mr. Lang brings 15+ years of global biopharma leadership across legal, corporate strategy, compliance, and business development.
His background includes guiding a company through an up to $10 billion acquisition by Pfizer, leadership roles tied to Phase 3 development and global approvals, and responsibility for ex-US operations; he will support moving aleniglipron into Phase 3 and strengthening operations.
Structure Therapeutics (NASDAQ: GPCR) reported positive Phase 2 ACCESS program topline data for oral GLP-1 receptor agonist aleniglipron. Placebo-adjusted mean weight loss at 44 weeks was -16.3% (180 mg) and -16.0% (240 mg); OLE 56-week loss reached -16.2% (120 mg).
Tolerability improved using a 2.5 mg starting dose (AE-related discontinuations 2.0–3.4%). No drug-induced liver injury or QTc prolongation observed across >625 participants. End-of-Phase 2 FDA meeting set for Q2 2026; Phase 3 initiation on track for 2H 2026.
Structure Therapeutics (NASDAQ: GPCR) reported positive Phase 2 aleniglipron results, including a placebo-adjusted 15.3% weight loss at 36 weeks (240 mg) and no observed weight-loss plateau. The company holds $1.4 billion in cash and short-term investments, expected to fund operations through end-2028.
Topline ACCESS II 44-week results are expected in Q1 2026 and a Phase 3 program is planned to start in 2H 2026; ACCG-2671 entered Phase 1 with data due 2H 2026.